|
2. Etiologie
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Evaluating Susceptibility to Pancreatic Cancer [ASCO]
|
|
|
|
|
|
An
ASCO provisional clinical opinion (PCO) offers timely clinical
direction to ASCO’s membership and other health care providers. This PCO
addresses identification and management of patients and family members
with possible predisposition to pancreatic adenocarcinoma.
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
New Blood Test Detects Early Stage Ovarian Cancer [University of Adelaide]
|
|
|
|
|
|
A
paper published this month in Biochemical and Biophysical Research
Communications has shown that the new test detected significant levels
of the cancer glycan in blood samples from over 90% of women with stage 1
ovarian cancer and in 100% of samples from later stages of the disease,
but not in any of the samples from healthy controls.
|
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
Bavencio falls short in ovarian cancer study [BiopharmaDive]
|
|
|
|
|
|
The
failure of Bavencio (avelumab) in ovarian cancer isn't entirely a
surprise, as checkpoint inhibitors have had less success in this tumor
type than in others like lung cancer and melanoma. None of the currently
approved checkpoint inhibitors are cleared for use in ovarian cancer in
the U.S.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Most FDA required post-marketing drug studies are missing [EPR]
|
|
|
|
|
|
A
study from Boston Children’s Hospital finds that only about a third of
these mandatory trials were completed within an average of seven years.
As a result, most new drug labels continue to lack information needed
for use in children, and most FDA-approved medications remain untested
in children.
|
|
|
|
|
|
|
|
FDA's Woodcock: 'The clinical trial system is broken' [BioparmaDive]
|
|
|
|
|
|
The
director for the Center for Drug Evaluation and Research pitched
platform trials with master protocols, which she argued can more
efficiently answer clinical questions. While this design can require
competitors to work together, Woodcock said she has seen a "groundswell"
of recent support.
|
|
|
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.6 Publications
|
|
|